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Parachlamydia and
Rhabdochlamydia: Emerging
Agents of Community-
Acquired Respiratory
Infections in Children
To the Editor—Besides viruses, Myco-
plasma pneumoniae and Chlamydia
pneumoniae are common causes of
community-acquired respiratory in-
fections (CARI) in children. However, the
causal agent of CARI remains unknown in
many cases [1]. Growing evidence sug-
gests that Chlamydia-related bacteria
might have a pathogenic role in humans
[2, 3]. Parachlamydia acanthamoebae and
Protochlamydia naegleriophila have been
detected in respiratory clinical samples
[4, 5], and the role of Parachlamydia
acanthamoebae in pneumonia is sup-
ported by in vitro studies and animal
models [6]. Rhabdochlamydia crassificans
and Rhabdochlamydia porcellionis are in-
tracellular pathogens of arthropods that
also belong to the Chlamydiales order
[7, 8]. A recent analysis suggests that
Rhabdochlamydia species might affect
morbidity and mortality in premature
newborns [9], but their role in respiratory
infections is unknown.
Using 3 previously described real-time
polymerase chain reactions (PCRs)
for the detection of P. acanthamoebae,
P. naegleriophila, and Rhabdochlamydia
spp. [4, 5, 9], we aimed at assessing the
prevalence and clinical significance of
these bacteria in respiratory secretions of
children. All available respiratory sam-
ples of children hospitalized between
September 2004 and October 2006 with
a diagnosis of CARI were retrospectively
tested. Tracheobronchitis was defined by
the presence of a new cough with at least
one of the following signs (dyspnea,
sputum, fever $38C) or a diagnosis of
upper respiratory tract infection in the
medical record. Pneumonia was con-
sidered in the presence of the above
criteria and a new infiltrate on chest
x-ray. As controls, we used respiratory
samples of 6 children hospitalized dur-
ing the same period without evidence of
respiratory infection at time of sampling.
Multiplex PCR assay for the detection of
M. pneumoniae and C. pneumoniae was
also performed using previously re-
ported primers and probes [10].
Twenty-nine patients were included (13
males, 16 females; median age, 5 years;
range, 3 months to 18 years). Most (90%)
respiratory samples were nasopharyngeal
secretions. Positive results for Chlamydia-
related bacteria were obtained in 14 (48%)
of 29 patients with CARI (2 Para-
chlamydia, 11 Rhabdochlamydia, 1 both
Para- and Rhabdochlamydia; Proto-
chlamydia was not recovered) and 0 (0%)
of 6 controls (P 5 .06). Considering only
cases of documented pneumonia (n5 21),
the rate of positive results was 52%
(P 5 .05 when compared with controls).
Clinical characteristics of the 14 patients
with CARI and positive PCR results for
Parachlamydia or Rhabdochlamydia
species are summarized in Table 1. An
alternative causal agent of pneumonia
was documented in 2 cases (M. pneu-
moniae and S. pneumoniae). Of the 12
patients without alternative etiology, 5
(42%) received a macrolide (to which
Chlamydia-related bacteria are suscepti-
ble). Interestingly, one patient who did
not respond to initial beta-lactam
monotherapy experienced a rapid im-
provement after start of clarithromycin.
In conclusion, our study revealed a high
prevalence of positive respiratory samples
for Parachlamydia and Rhabdochlamydia
species. A similar prevalence has been re-
cently reported in premature neonates
with respiratory distress syndrome [9],
which suggests that airways colonization
with these Chlamydia-related bacteria is
common. Their pathogenic role in CARI
is supported by the fact that these bacteria
were not recovered from respiratory
samples of patients without evidence of
respiratory infection and were the only
possible causal agents of pneumonia in 12
of 14 cases.
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Table 1. Clinical Characteristics of Respiratory Infection in Children With Positive PCR Results for Chlamydia-Related Bacteria
Sex/age/
underlying condition
Type of pulmonary
infection
Other symptoms/
signs
Alternative
etiology
Supportive
measures Treatment (response)
Parachlamydia acanthamoebae
F/13 y/pinealoblastoma
(neutropenia)
Bilateral interstitial
pneumonia
Enterocolitis . . Meropenem,
vancomycin (complete)
M/15 y/- Unilateral alveolar
pneumonia
Pleural effusion . . Amoxicillin/clavulanate,
clarithromycin
(complete)
Rhabdochlamydia spp.
F/1 y/- Tracheobronchitis . S.pneumoniae
(urinary antigen)
Invasive
ventilation
Ceftriaxone, clarithromycin
(complete)
F/2 y/- Unilateral alveolar
pneumonia
. . Oxygen supply Amoxicillin/clavulanate
(complete)
M/2 y/- Unilateral alveolar
pneumonia
Rhinitis, pleural
effusion
. . Amoxicillin/clavulanate,
clarithromycin
(complete)
M/2 y/cystic fibrosis Bilateral alveolar
pneumonia
. . . Amoxicillin/clavulanate
(complete)
F/3 y/- Bilateral alveolar
pneumonia
Rhinitis, pharyngitis,
seizures
M. pneumoniae
(nosal swab, PCR)
. Clarithromycin
(complete)
M/5 y/osteosarcoma
(neutropenia)
Unilateral alveolar
pneumonia
Rhinitis . . Ceftriaxone, amikacin
(complete)
F/9 y/
methylmalonicacidemia
Unilateral interstitial
pneumonia
. . . Amoxicillin/clavulanate
(no response); then:
clarithromycin
(complete)
F/11 y/- Unilateral interstitial
pneumonia
Otitis media . Oxygen supply Clarithromycin (complete)
F/14 y/cystic fibrosis Unilateral alveolar
pneumonia
. . Non invasive
mechanical
ventilation
Imipenem, ciprofloxacin
(complete)
F/15 y/- Unilateral alveolar
pneumonia
Pleural effusion . Oxygen supply Amoxicillin/clavulanate,
clarithromycin
(complete)
M/17 y/- Tracheobronchitis . . . No treatment (complete)
Parachlamydia acanthamoebae and Rhabdochlamydia spp.
M/1 month/- Tracheobronchitis Conjunctivitis . . No treatment (complete)
NOTE. y, year-old.
CORRESPONDENCE d CID 2011:53 (1 September) d 501
